Article ID Journal Published Year Pages File Type
2486978 Journal of Pharmaceutical Sciences 2009 8 Pages PDF
Abstract
Genetically modified Lactococcus lactis (L. lactis), a probiotic bacterium, able to secrete β-lactamase (29 kDa), was used as a vector for the oral delivery of β-lactamase to the rats. Three different doses of L. lactis were administered to the rats, and the resulted β-lactamase oral bioavailability was studied, and compared to the solution form. The oral administration of 1.2 × 107 , 3 × 107, and 8 × 107 colony-forming units of L. lactis led to 145, 209, and 364 mU of β-lactamase absorbed, and the corresponding bioavailability was 8.7%, 15.5%, and 20.8% based on the in vitro production of β-lactamase by L. lactis. The oral administration of 504 mU and 1008 mU β-lactamase free solution resulted in 30 and 47 mU absorbed, a bioavailability of 5.9% and 4.7%, respectively. L. lactis significantly (p < 0.01) increased the oral bioavailability compared to the free solution form. A significant (p < 0.01) increase in the MAT value as compared to the solution, demonstrated that L. lactis can be used as a sustained delivery system. In conclusion, there is a linear relationship between L. lactis dose and these absorption PK parameters within L. lactis dose range of the current study.
Related Topics
Health Sciences Pharmacology, Toxicology and Pharmaceutical Science Drug Discovery
Authors
, ,